Clinical-stage focus Target pairing with specialty CROs and pharma partners interested in orphan diseases and high-need pulmonary therapies, leveraging ARV-1801 Phase III program for cystic fibrosis to accelerate partnerships and co-development discussions.

Rare disease positioning Position Arrevus as a partner for rare disease initiatives and FDA Orphan Drug Designations to unlock incentives, potential fast-track interactions, and priority review considerations that could attract biotech investors and licensing deals.

Strategic partnerships Explore collaboration opportunities with companies focusing on infectious diseases, antibiotics, and antimicrobial resistance, including potential for in-licensing ARV-1502 preclinical assets and wound infection programs to broaden portfolio and revenue streams.

Small team agility Leverage the small headcount as a selling point for nimble collaborations, turnkey partnerships, and streamlined decision-making with large pharma seeking fast-execution pilots or milestone-driven deals.

Funding inflection Highlight existing grant and debt financing history to reassure potential partners of validated funding support, while pursuing co-funding or grant-aligned programs to de-risk joint development and expand opportunity pipelines.